Skip to main content

Table 2 Efficacy ( N = 77)

From: Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study

Outcome

Months

95% CI

Median time to progression

11.9

10.8–13.1

Median progression-free survival

11.8

10.7–13.0

Median overall survival

24.8

19.9–29.7

Response to treatment

N

%

Complete response

4

5.2

Partial response

35

45.5

Stable disease

26

33.8

Progressive disease

5

6.5

Not evaluable

7

9.1

Response rates

%

95% CI

Overall response rate

50.6

39.1–62.0

Disease control rate

84.4

74.0–91.3

  1. Abbreviation: CI confidence interval.